NEW YORK, Feb. 5 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will be presenting at the following upcoming Investor Conferences: Thursday, February 7th, 2008 - 10:20 AM ET: Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference Grand Hyatt Hotel
New York City Monday, February 11, 2008 - 12:30 PM ET:
BIO CEO & Investor Conference
Waldorf=Astoria Hotel
New York City Each of Mr. Weiss' presentations will be webcast live and may be accessed from the Investor Information page of the Company's Website at http://investors.keryx.com/. An archived version of each presentation webcast will be available following the conclusion of the live presentation.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx's lead compound under development is Sulonex(TM) (sulodexide oral gelcap), previously referred to as KRX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. Sulonex is in a pivotal Phase 3 and Phase 4 clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Keryx is developing Zerenex(TM), an oral, iron- based compound that has the capacity to bind phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated serum phosphorous levels) in patients with end-stage renal disease. Keryx is also developing clinical-stage oncology compounds, including KRX-0401, a novel, first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth, and a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. Keryx also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.
Keryx Contact:
Lauren Fischer
Keryx Biopharmaceuticals, Inc. Tel: 212.531.5965
DATASOURCE: Keryx Biopharmaceuticals, Inc.
CONTACT: Lauren Fischer of Keryx Biopharmaceuticals, Inc., +1-212-531-5965, Web site: http://investors.keryx.com/
|